JMP Genomics for SAS^® Drug Development

The power to integrate molecular information with clinical outcomes

The era of personalized medicine has arrived, with targeted treatments that promise improved safety and efficacy hitting the market. By combining molecular information with clinical outcomes, scientists are discovering new ways to minimize the risks and maximize the benefits of prescription medicines. In the US, guidance documents from the FDA emphasize its expectation for molecular information to accompany New Drug Applications in order to drive and support better clinical decision making.

SAS provides the premier research and development platform for enabling this type of science. We've combined a comprehensive library of genomics and proteomics analysis procedures with the industry-leading data management and analytic capabilities of SAS Drug Development to deliver a fully configurable, collaborative biomarker research and clinical analysis system that promotes innovation and research quality within a compliance-enabling framework.

By integrating prebuilt genomics and proteomics analysis procedures with SAS Drug Development, SAS enables life science organizations to:

• Ensure collaboration, compliance and traceability. Facilitate regulatory compliance, meet traceability requirements for analytic results and simplify global collaboration while incorporating molecular information into clinical decision making.
• Minimize risk. Use the collaborative biomarker analysis system to bring safer, more-effective drugs to market faster.
• Maximize scalability. Take advantage of the processing power of the SAS Drug Development server environment for complex, resource-intensive genomic analyses.

The power to visualize
The molecular routines are powered by JMP software – a powerful, dynamic data visualization and statistical analysis solution. More than 90 processes for molecular analyses – fully integrated with SAS Drug Development – are contained within the software's genomics and proteomics analysis modules:

• Genetics. For genetic marker data, case-control or pedigree experiments. Useful for characterizing genetic variability and evaluating its association with biological effects, such as disease or adverse events.
• Microarray. For gene expression or RNA transcript abundance data. Useful for investigating gene utilization to understand disease or biological processes.
• Proteomics. For spectral data on peptides or metabolites. Useful for identifying protein biomarkers and their association with disease or traits.

SAS Drug Development
SAS Drug Development enables collaboration among scientists and other industry professionals by allowing them to access, explore and investigate research data from any source – enabling easier identification of medically relevant trends and more confident product portfolio management decisions. The solution lets you create an institutional memory of research and development information. The result is a better understanding of the safety and efficacy of your therapies and less time spent searching for and aggregating data for analysis.

Additional SAS technologies for genomics
SAS/Genetics software is designed specifically for genetics research, enabling you to study genetic markers individually, examine the relationship between multiple markers and find associations between markers and traits using case-control or family data. Because you can depict results graphically, they're easier to understand and share.